Literature DB >> 23701272

Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.

Shih-Ku Lin1.   

Abstract

Substance abuse or addictive disorder is a global problem. A greater understanding of the associated changes in brain pathophysiology supports the notion that pharmacological treatments are part of the necessary treatment options. Craving is a core symptom of addictive disorder. It refers to a strong desire to use drugs again either to re-experience positive effects or to diminish negative experiences. Currently there are a number of medicines that are effective in the treatment of addictive disorders. These medications can either be for substitution (same pharmacological effect as the abused substance) or anticraving (decrease the craving of the abused substance). In this MEDLNE based review, specific compounds (naltrexone, acamprosate, topiramate, disulfiram, baclofen, N-acetylcysteine and bupropion) were selected that are known to diminish desire to use (anticraving effect) and that have been trialled for a number of different substance addictive disorders. Their therapeutic potential in clinical practice is discussed in light of their efficacy.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  addiction; anticraving; craving; drug dependence

Mesh:

Year:  2014        PMID: 23701272      PMCID: PMC4014026          DOI: 10.1111/bcp.12163

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  137 in total

1.  The mesopontine rostromedial tegmental nucleus: an integrative modulator of the reward system.

Authors:  Heather N Lavezzi; Daniel S Zahm
Journal:  Basal Ganglia       Date:  2011-11

2.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

Review 3.  Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.

Authors:  Philipp P Lobmaier; Nikolaj Kunøe; Michael Gossop; Helge Waal
Journal:  CNS Neurosci Ther       Date:  2011-12       Impact factor: 5.243

4.  Determination of GABA, glutamate and carbamathione in brain microdialysis samples by capillary electrophoresis with fluorescence detection.

Authors:  Swetha Kaul; Morris D Faiman; Craig E Lunte
Journal:  Electrophoresis       Date:  2011-01       Impact factor: 3.535

5.  One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment.

Authors:  K M Carroll; C Nich; S A Ball; E McCance; T L Frankforter; B J Rounsaville
Journal:  Addiction       Date:  2000-09       Impact factor: 6.526

6.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Authors:  Maurizio Fava; A John Rush; Michael E Thase; Anita Clayton; Stephen M Stahl; James F Pradko; J Andrew Johnston
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

7.  Disulfiram, an option for the treatment of pathological gambling?

Authors:  Jochen Mutschler; Mira Bühler; Martin Grosshans; Alexander Diehl; Karl Mann; Falk Kiefer
Journal:  Alcohol Alcohol       Date:  2010-01-18       Impact factor: 2.826

8.  Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.

Authors:  R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam
Journal:  JAMA       Date:  1986-09-19       Impact factor: 56.272

9.  Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence.

Authors:  Kyle M Kampman; Helen M Pettinati; Kevin G Lynch; Hu Xie; Charles Dackis; David W Oslin; Thorne Sparkman; Tiffany Sharkoski; Charles P O'Brien
Journal:  Addict Behav       Date:  2009-03-24       Impact factor: 3.913

10.  Cognitive control of drug craving inhibits brain reward regions in cocaine abusers.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Frank Telang; Jean Logan; Millard Jayne; Yeming Ma; Kith Pradhan; Christopher Wong; James M Swanson
Journal:  Neuroimage       Date:  2009-11-11       Impact factor: 6.556

View more
  4 in total

1.  Substance use outcomes in cocaine-dependent tobacco smokers: A mediation analysis exploring the role of sleep disturbance, craving, anxiety, and depression.

Authors:  Theresa M Winhusen; Jeff Theobald; Daniel F Lewis
Journal:  J Subst Abuse Treat       Date:  2018-10-26

2.  Topiramate increases the rewarding properties of cocaine in young-adult mice limiting its clinical usefulness.

Authors:  M C Arenas; A Mateos-García; C Manzanedo; M Rodríguez-Arias; M A Aguilar; F Navarrete; M S García Gutiérrez; J Manzanares; J Miñarro
Journal:  Psychopharmacology (Berl)       Date:  2016-09-05       Impact factor: 4.530

Review 3.  Precision in Addiction Care: Does It Make a Difference?

Authors:  Jaap van der Stel
Journal:  Yale J Biol Med       Date:  2015-11-24

4.  Intermittent Theta Burst Stimulation of the Prefrontal Cortex in Cocaine Use Disorder: A Pilot Study.

Authors:  Angela Sanna; Liana Fattore; Paola Badas; Giorgio Corona; Viola Cocco; Marco Diana
Journal:  Front Neurosci       Date:  2019-07-25       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.